Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 5:48 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 197 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Anticonvulsant Clear all
Completed Phase 2 Interventional

New Drugs in the Treatment of Mood Disorders

NCT00001482
View directory record Official record
Conditions
Anxiety Disorder, Mood Disorder, Psychotic Disorder
Interventions
Lamotrigine (Lamictal® (Registered Trademark), Gabapentin (Neurontin® (Registered Trademark))
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
Not listed
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 2, 2026, 5:48 PM EDT
Withdrawn Phase 4 Interventional

Does Pregabalin Improve Symptoms of Anxiety in Patients With Epilepsy? A Comparison With Sertraline

NCT01309074
View directory record Official record
Conditions
Epilepsy, Anxiety
Interventions
Pregabalin-Lyrica, Sertraline
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 1, 2023 · Synced Sep 2, 2026, 5:48 PM EDT
Withdrawn Phase 2 Interventional

Evaluate the Efficacy of BGG492 as Adjunctive Treatment in Patients With Refractory Partial Onset Seizures

NCT01167335
View directory record Official record
Conditions
Partial Onset Seizures
Interventions
BGG492, Placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
3
States / cities
Mobile, Alabama • Baltimore, Maryland • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 30, 2012 · Synced Sep 2, 2026, 5:48 PM EDT
Terminated Phase 1 Interventional

Erlotinib in Treating Patients With Progressive Glioblastoma Multiforme

NCT00227032
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
erlotinib hydrochloride
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 5, 2012 · Synced Sep 2, 2026, 5:48 PM EDT
Completed Phase 2 Interventional Results available

A Trial of the Efficacy and Safety of CVL-865 as Adjunctive Therapy in the Treatment of Focal Onset Seizures

NCT04244175
View directory record Official record
Conditions
Seizures
Interventions
Placebo, CVL-865
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 75 Years
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
37
States / cities
Little Rock, Arkansas • Downey, California • Loma Linda, California + 33 more
Source: ClinicalTrials.gov public record
Updated May 29, 2025 · Synced Sep 2, 2026, 5:48 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study to Evaluate Pregabalin and Acetaminophen in Healthy Volunteers

NCT04265456
View directory record Official record
Conditions
Postoperative Pain
Interventions
Pregabalin 100mg, Acetaminophen 1300mg
Drug
Lead sponsor
Nevakar, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Pasadena, California
Source: ClinicalTrials.gov public record
Updated Aug 4, 2020 · Synced Sep 2, 2026, 5:48 PM EDT
Completed Phase 3 Interventional Results available

A Placebo-controlled Study of Efficacy & Safety of 2 Trough-ranges of Everolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex (TSC) & Refractory Partial-onset Seizures

NCT01713946
View directory record Official record
Conditions
Tuberous Sclerosis Complex-associated Refractory Seizures
Interventions
RAD001, Placebo, Antiepileptic drug (1 to 3 only), open label RAD001 (only used for post-extension phase)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
2 Years to 65 Years
Enrollment
366 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
22
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2018 · Synced Sep 2, 2026, 5:48 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Eslicarbazepine Acetate Monotherapy in Subjects With Partial Epilepsy Not Well Controlled by Current Antiepileptic Drugs

NCT00866775
View directory record Official record
Conditions
Epilepsy With Simple or Complex Partial Onset Seizures
Interventions
Eslicarbazepine acetate
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
16 Years to 70 Years
Enrollment
193 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
103
States / cities
Birmingham, Alabama • Mobile, Alabama • Northport, Alabama + 82 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2016 · Synced Sep 2, 2026, 5:48 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Clinical Study in Healthy Volunteers to Investigate the Neurocognitive Effects of a New Antiepileptic Drug: Brivaracetam

NCT00736931
View directory record Official record
Conditions
Epilepsy
Interventions
Brivaracetam, levetiracetam, lorazepam, placebo
Drug · Other
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated May 27, 2012 · Synced Sep 2, 2026, 5:48 PM EDT
Terminated Phase 2 Interventional Results available

An Open-label Extension Trial of CVL-865 as Adjunctive Therapy in the Treatment of Focal Onset Seizures

NCT04686786
View directory record Official record
Conditions
Seizures
Interventions
CVL-865
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 75 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
26
States / cities
Little Rock, Arkansas • New Haven, Connecticut • Gulf Breeze, Florida + 22 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2025 · Synced Sep 2, 2026, 5:48 PM EDT
Completed Phase 1 Interventional

Pharmacokinetics (PK) Study of AC480 for Recurrent Glioma

NCT00979173
View directory record Official record
Conditions
Glioma
Interventions
AC480
Drug
Lead sponsor
Annick Desjardins
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 28, 2014 · Synced Sep 2, 2026, 5:48 PM EDT
Terminated No phase listed Observational

A Health Economic Study Evaluating the Brain Sentinel® GTC Seizure Detection and Information Systems Impact on Epilepsy and Healthcare Utilization

NCT02752373
View directory record Official record
Conditions
Epilepsy
Interventions
Brain Sentinel Seizure Detection and Information System
Device
Lead sponsor
Brain Sentinel
Other
Eligibility
2 Years to 99 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 19, 2017 · Synced Sep 2, 2026, 5:48 PM EDT
Completed Not applicable Interventional Results available

Phenytoin and Multidose Activated Charcoal

NCT00823264
View directory record Official record
Conditions
Phenytoin Toxicity
Interventions
Activated Charcoal
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 10, 2014 · Synced Sep 2, 2026, 5:48 PM EDT
Completed Phase 3 Interventional Results available

Zonisamide Treatment of Alcohol Use Disorder: an Evaluation of Efficacy and Mechanism of Action

NCT02900352
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Zonisamide, Placebo
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
21 Years to 70 Years
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
4
States / cities
Farmington, Connecticut • New Haven, Connecticut • West Haven, Connecticut + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2022 · Synced Sep 2, 2026, 5:48 PM EDT
Completed Phase 3 Interventional Results available

Paramedic Treatment of Prolonged Seizures by Intramuscular Versus Intravenous Anticonvulsant Medications

NCT00809146
View directory record Official record
Conditions
Status Epilepticus
Interventions
Intramuscular route of active treatment, Intravenous route of active treatment
Drug
Lead sponsor
Robert Silbergleit
Other
Eligibility
Not listed
Enrollment
1,023 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
17
States / cities
Tucson, Arizona • Palo Alto, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2016 · Synced Sep 2, 2026, 5:48 PM EDT
Completed Not applicable Interventional Results available

Auricular Acupuncture For The Treatment Of Non-Epileptic Seizures

NCT01919307
View directory record Official record
Conditions
Convulsion, Non-Epileptic
Interventions
Auricular acupuncture
Other
Lead sponsor
Denver Health and Hospital Authority
Other
Eligibility
18 Years to 75 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 4, 2018 · Synced Sep 2, 2026, 5:48 PM EDT
Completed Not applicable Interventional

Counseling on the Interaction of Hormonal Contraceptives and Antiepileptics

NCT02485756
View directory record Official record
Conditions
Epilepsy
Interventions
Educational handout
Other
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jun 6, 2019 · Synced Sep 2, 2026, 5:48 PM EDT
Completed Phase 4 Interventional

Equivalence Among Antiepileptic Drug Generic and Brand Products in People With Epilepsy: Single-Dose 6-Period Replicate Design (EQUIGEN Single-Dose Study)

NCT01733394
View directory record Official record
Conditions
Epilepsy
Interventions
Lamotrigine Generic "A" Lamotrigine Generic "B" Lamotrigine "Brand", lamotrigine
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
8
States / cities
Birmingham, Alabama • Des Moines, Iowa • Iowa City, Iowa + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2017 · Synced Sep 2, 2026, 5:48 PM EDT
Terminated Phase 4 Interventional Results available

Investigation of Cannabidiol for Reduction of NeuroInflammation in Chronic Back Pain

NCT03891264
View directory record Official record
Conditions
Back Pain, Low
Interventions
Cannabidiol
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 3, 2022 · Synced Sep 2, 2026, 5:48 PM EDT
Completed Not applicable Interventional

The Impact of Electroencephalographic (EEG) Seizure Treatment in Neonatal Encephalopathy

NCT01027715
View directory record Official record
Conditions
Seizures, Encephalopathy
Interventions
EEG monitoring and treatment of EEG seizures
Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
1 Hour to 72 Hours
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 9, 2015 · Synced Sep 2, 2026, 5:48 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Developmental Delay in Children Exposed During Pregnancy to Either Lamotrigine,Sodium Valproate, or Carbamazepine

NCT01097720
View directory record Official record
Conditions
Autism, Developmental Delay, Birth Defects
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
36 Months to 83 Months
Enrollment
298 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 1, 2010 · Synced Sep 2, 2026, 5:48 PM EDT
Completed Phase 2 Interventional Results available

Phase II Avastin + Bortezomib for Patients With Recurrent Malignant Glioma

NCT00611325
View directory record Official record
Conditions
Glioblastoma, Gliosarcoma
Interventions
Avastin, Bortezomib
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 11, 2014 · Synced Sep 2, 2026, 5:48 PM EDT
Withdrawn Phase 2Phase 3 Interventional Accepts healthy volunteers

Efficacy of Ketamine Infusion Compared With Traditional Anti-epileptic Agents in Refractory Status Epilepticus

NCT03115489
View directory record Official record
Conditions
Refractory Epilepsy
Interventions
Traditional Treatment (Group T), Ketamine Infusion (Group K)
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 100 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated May 20, 2021 · Synced Sep 2, 2026, 5:48 PM EDT
Completed Phase 2 Interventional

Topiramate in the Treatment of Sciatica

NCT00011804
View directory record Official record
Conditions
Sciatica
Interventions
Topiramate
Drug
Lead sponsor
National Institute of Dental and Craniofacial Research (NIDCR)
NIH
Eligibility
Not listed
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 2, 2026, 5:48 PM EDT